Core Viewpoint - Junshi Biosciences (01877) experienced a significant stock increase of over 10%, attributed to the approval of clinical trial application for JT118, a dual-target recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Group 1: Clinical Trial Approval - Junshi Biosciences' subsidiary, Shanghai Juntuo Biopharmaceutical Technology Co., Ltd., received the Drug Clinical Trial Approval Notification from the National Medical Products Administration for JT118 [1] - JT118 is a recombinant protein vaccine composed of monkeypox virus antigens A35 and M1, demonstrating significant protective effects in preclinical studies against both vaccinia virus and monkeypox virus in large animal models, with good safety profiles [1] Group 2: Research Recognition - Multiple research outcomes from Junshi Biosciences, including the anti-BTLA monoclonal antibody tifcemalimab and the anti-PD-1 monoclonal antibody treprilumab, have been selected for oral presentations and posters at the 2025 World Lung Cancer Conference (WCLC) scheduled for September 6-9, 2025, in Barcelona, Spain [1]

Group 1 - Junshi Bioscience (01877) shares rose over 10%, currently up 11.03% at HKD 34.22, with a trading volume of HKD 516 million [1] - The company announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of JT118 injection, a "dual" recombinant protein vaccine aimed at preventing monkeypox virus infection [1] - Preclinical studies indicate that JT118 shows significant protective effects against vaccinia virus/monkeypox virus infections in small animal models, with good safety profiles [1] Group 2 - The 2025 World Lung Cancer Conference (WCLC) will be held from September 6 to 9, 2025, in Barcelona, Spain [1] - Junshi Bioscience's innovative products, including anti-BTLA monoclonal antibody tifcemalimab and anti-PD-1 monoclonal antibody teriprizumab, have multiple research results selected for oral presentations and posters at the conference, showcasing the latest advancements in lung cancer research [1]